EUVIMEDEUVIMED entdecken
Crossref

Design of casein‐based nanocarriers for targeted delivery of daunorubicin to leukemia cells

Ali Beigrezaei, Ronak Rafipour iD

Biotechnology and Applied Biochemistry · 2025

DOI: 10.1002/bab.2662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2025. Verfasst von Ali Beigrezaei und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Kermanshah Branch, Islamic Azad University, Kermanshah, Iran. Hauptthemen laut MEDLINE: Caseins, Daunorubicin, Drug Carriers, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daunorubicin (DAU) is a chemotherapy drug approved for the treatment of some cancers. However, the clinical compatibility of DAU is limited due to its lack of specificity and its highly toxic effects, which interfere with normal cells. This toxicity can be reduced with nanocarriers and targeted drug delivery systems. In this study, to develop the drug delivery of DAU, the surface of synthesized nanoparticles was modified by folic acid to target cancer cells optimally. Encapsulation of DAU in protein sodium caseinate (NaCAS) was done by adding calcium ions to bring the casein (CAS) in the solution to a micellar structure to synthesize dense nanoparticles. Fourier‐transform infrared spectroscopy transmission, fluorescence spectroscopy, UV–Vis spectroscopy, field emission scanning electron microscopy, and zeta potential studies designed and distinguished the synthesized nanocomplexes. The results showed that CAS nanoparticles successfully encapsulated DAU, and the protein surface was targeted by folic acid. Light scattering analysis determined that the particles with a scattering index number of 306.0 and an average size of 8.117 nm were synthesized. The zeta potential of CAS micelles is more harmful than CAS nanoparticles. This is because calcium ions are added during the formation of CAS nanoparticles during the drug‐loading stages. These studies prove that the synthesized “NaCAS‐DAU” and “NaCAS‐DAU‐folic acid” complexes can be favorable carriers in the targeted drug delivery of cancer drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CaseinsDaunorubicinDrug CarriersNanoparticlesLeukemiaDrug Delivery SystemsAntibiotics, AntineoplasticHumansFolic AcidParticle Size

Stichwörter der Autor:innen

cancercaseincharacterizationencapsulationfolic acidtargeted drug delivery

Substanzen

CaseinsDaunorubicinDrug CarriersAntibiotics, AntineoplasticFolic Acid

Autor:innen und Institutionen

  • Department of Chemistry, Kermanshah Branch, Islamic Azad University, Kermanshah, Iran.

ORCID-Profile: Ronak Rafipour

Zitieren

APA

Beigrezaei, A., & Rafipour, R. (2025). Design of casein‐based nanocarriers for targeted delivery of daunorubicin to leukemia cells. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2662

Vancouver

Beigrezaei A, Rafipour R. Design of casein‐based nanocarriers for targeted delivery of daunorubicin to leukemia cells. Biotechnology and Applied Biochemistry. 2025. doi:10.1002/bab.2662

BibTeX
@article{Beigrezaei2025,
  author = {Beigrezaei, Ali and Rafipour, Ronak},
  title = {Design of casein‐based nanocarriers for targeted delivery of daunorubicin to leukemia cells},
  journal = {Biotechnology and Applied Biochemistry},
  year = {2025},
  doi = {10.1002/bab.2662}
}
Kostenlos starten →